Article Details

AbbVie-Roche's Venclexta Shows Progression-Free Survival Of 74% In CLL Patients After Three ...

Retrieved on: 2021-06-11 14:11:15

Tags for this article:

Click the tags to see associated articles and topics

AbbVie-Roche's Venclexta Shows Progression-Free Survival Of 74% In CLL Patients After Three .... View article details on hiswai:

Excerpt

AbbVie-Roche's Venclexta Shows Progression-Free Survival Of 74% In CLL ... Genentech, a unit of Roche Holdings AG (OTC: RHHBY), and its ...

Article found on: www.benzinga.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up